AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 474 participants.
Also called NCT07030595
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 474 participants
- Sponsor
- Alebund Pharmaceuticals
- Registry
-
NCT07030595
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT07030595. Randomized; no masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2024-10-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
- Acronym
- RESPOND-1
- Condition
- ESRD (End Stage Renal Disease)
- Condition
- Hyperphosphatemia
- Condition
- Hyperphosphatemia in Chronic Kidney Disease
- Condition
- Dialysis
- Condition
- Chronic Kidney Disease, Receiving Dialysis
- Intervention (Drug)
- AP301
- Intervention (Drug)
- Sevelamer carbonate (Renvela®)
- Intervention (Drug)
- AP301 Low Dose
- Lead sponsor
- Alebund Pharmaceuticals
Record details
- Record id
cardio:ct-nct07030595- Content hash
275d49ea3c969f1f6026e3bcc6d17c5d8e285bb4755a1e80b751f0ef57459366